Skip to main content

Table 2 GVHD incidences in allogeneic HSCT recipients

From: Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia

Parameters N = 24, (%)
Acute GVHD
 I 4 (16.7%)
 II 2 (8.35%)
 III 4 (16.7%)
 IV 2 (8.35%)
Chronic GVHD
 Lim 3 (12.5%)
 Ext 3 (12.5%)
  1. HSCT hematopoietic stem cell transplantation, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, Ext extensive, Lim limited